Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-01-24
2006-01-24
Brumback, Brenda (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S134100, C424S178100, C424S192100, C530S350000, C530S402000, C530S815000, C514S012200, C514S023000, C536S023500, C435S320100, C435S069100, C435S325000, C435S252300
Reexamination Certificate
active
06989147
ABSTRACT:
Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor necrosis binding proteins by recombinant genetic engineering techniques.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4522750 (1985-06-01), Ades et al.
patent: 4560649 (1985-12-01), Saxena et al.
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4670563 (1987-06-01), Jansen et al.
patent: 4675285 (1987-06-01), Clark et al.
patent: 4677027 (1987-06-01), Porath et al.
patent: 4696980 (1987-09-01), Porath
patent: 4760067 (1988-07-01), Firestone
patent: 4766106 (1988-08-01), Katre et al.
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4917888 (1990-04-01), Katre et al.
patent: 4931544 (1990-06-01), Katre et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 4966888 (1990-10-01), Saxena et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5093475 (1992-03-01), Carroll et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5171264 (1992-12-01), Merrill
patent: 5211945 (1993-05-01), Wallach et al.
patent: 5214131 (1993-05-01), Sano et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5344915 (1994-09-01), LeMaire et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5446090 (1995-08-01), Harris
patent: 5453490 (1995-09-01), Hageman et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5569779 (1996-10-01), Sabahi et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5681566 (1997-10-01), Stevenson
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5712155 (1998-01-01), Smith et al.
patent: 5739208 (1998-04-01), Harris
patent: 5747639 (1998-05-01), Seely
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5811261 (1998-09-01), Wallach et al.
patent: 5863786 (1999-01-01), Feldmann et al.
patent: 5958409 (1999-09-01), Turk et al.
patent: 2003743 (1990-05-01), None
patent: 39 10 323 (1989-10-01), None
patent: 0 040 506 (1981-11-01), None
patent: 0 092 918 (1983-11-01), None
patent: 0 094 844 (1983-11-01), None
patent: 0 154 316 (1985-09-01), None
patent: 0 169 112 (1986-01-01), None
patent: 0 225 579 (1987-06-01), None
patent: 0 247 860 (1987-12-01), None
patent: 0 259 863 (1988-03-01), None
patent: 0 308 378 (1989-03-01), None
patent: 0 154 316 (1989-09-01), None
patent: 0 334 165 (1989-09-01), None
patent: 0 343 684 (1989-11-01), None
patent: 0 372 752 (1990-06-01), None
patent: 0 386 289 (1990-09-01), None
patent: 0 393 438 (1990-10-01), None
patent: 0 395 853 (1990-11-01), None
patent: 0 398 327 (1990-11-01), None
patent: 0 412 486 (1991-02-01), None
patent: 0 417 563 (1991-03-01), None
patent: 0 418 014 (1991-03-01), None
patent: 0 422 339 (1991-04-01), None
patent: 0 433 900 (1991-06-01), None
patent: 0 512 528 (1992-11-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0 622 394 (1994-11-01), None
patent: 2 218 101 (1989-11-01), None
patent: 2 246 569 (1992-02-01), None
patent: 90339 (1989-05-01), None
patent: 02040399 (1990-02-01), None
patent: 62-185029 (1997-08-01), None
patent: WO 87/00056 (1987-01-01), None
patent: WO 88/00837 (1988-02-01), None
patent: WO 89/05145 (1989-06-01), None
patent: WO 89/06546 (1989-07-01), None
patent: WO 89/09220 (1989-10-01), None
patent: WO 90/04413 (1990-05-01), None
patent: WO 90/04650 (1990-05-01), None
patent: WO 90/05755 (1990-05-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 90/13575 (1990-11-01), None
patent: WO 91/03553 (1991-03-01), None
patent: WO 91/05047 (1991-04-01), None
patent: WO 91/07190 (1991-05-01), None
patent: WO 91/16437 (1991-10-01), None
patent: WO 92/01002 (1992-01-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/01474 (1992-02-01), None
patent: WO 92/04384 (1992-03-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 92/15682 (1992-09-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 92/16555 (1992-10-01), None
patent: WO 93/01498 (1993-01-01), None
patent: WO 94/01483 (1994-01-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 94/06058 (1995-03-01), None
patent: WO 95/13312 (1995-05-01), None
patent: WO 95/34326 (1995-12-01), None
patent: WO 96/19459 (1996-06-01), None
patent: WO 97/32607 (1997-09-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Chen et al., Journal of Biological Chemistry, vol. 270, No. 6, pp. 2874-2878, Feb. 1995.
The Cytokine Facts Book, Callard and Gearing, Eds., Academic Press, 1994.
Abuchowski, et al., “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase,”Journal of Biological Chemistry, 252 (11): 3582-3586 (1977).
Aggarwal, et al., “Characterization of Receptors for Human Tumour Necrosis Fator and Their Regulation by Γ- Interferon”,Nature, 318: 665-667 (1985).
Akerblom, et al., “Preparation and Characterization of Conjugates of Monoclonal Antibodies and Staphylococcal Enterotoxin A Using a New Hydrophilic Cross-Linker,”Bioconjugate Chem., 4:455-466 (1993).
Anderson, et al., “Quantitative Filter Hybridisation,” Nucleic Acid Hybridization: A Practical Approach, Hawes, et al. (ed)., pp. 73-111 (1985).
Ashkenazi, et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,”PNAS88: 10535-10539 (1991).
Baglioni, et al., “Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition,”Journal of Biological Chemistry, 260 (25): 13395-13397 (1985).
Baker, et al., “Inhibition of EAE by TNF-Receptor Fusion Proteins,”J. Neuroimmunology, 54 (1-2): 151 Abstract P16.01 (1992).
Bakouche, et al., “Plasma Membrane-Associate Tumor Necrosis Factor, A Non-Integral Membrane Protein Possibly Bound to Its Own Receptor”,J. Immunol.140: 1142-1147 (1988).
Banner, et al., “Crystal Structure of the Soluble Human 55 kD TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”,Cell.73: 431-445 (1993).
Beutler, et al., “Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin”,Science, 229:869-871 (1985).
Beutler and Cerami, “The Biology of Cachectin/TNF-A Primary Mediator of the Host Response”,Ann. Rev. Immunol., 7:625-655 (1989).
Bevilacqua, et al., “Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1,”Proc. Natl. Acad. Sci. USA, 83: 4533-4537 (1986).
Binkert, et al., “Cloning, Sequence Analysis and Expression of a cDNA Encoding a Novel Insulin-like Growth Factor Binding Protein (IGFBP-2),”The EMPO J.8 (9):2497-2502 (1989).
Bourdon, et al., “Structure-function Relationships of Hirulog Peptide Interactions with Thrombin,”FEBS294:163-166 (1991).
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247: 1306-131
Edwards III Carl K.
Fisher Eric F.
Kieft Gary L.
Amgen Inc.
Brumback Brenda
McDonnell & Boehnen Hulbert & Berghoff
O'Hara Eileen B
LandOfFree
Truncated soluble tumor necrosis factor type-I and type-II... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated soluble tumor necrosis factor type-I and type-II..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated soluble tumor necrosis factor type-I and type-II... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3566624